Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Medicines & Healthy Lifestyle

Surgical vs Endoscopic Resection for High-Risk T1 Colorectal Cancer

admin by admin
August 28, 2022
in Medicines & Healthy Lifestyle


Surgical resection increases overall survival and recurrence-free survival in patients with high-risk T1 colorectal cancer (CRC); however, endoscopic resection with subsequent intensive surveillance may be a less invasive alternative for a specific subgroup of high-risk T1 CRC patients, according to study findings published in Gastrointestinal Endoscopy.

Of 803 total patients, researchers analyzed clinical outcomes of 547 patients with high-risk T1 CRC, who underwent either surgical (n=466) or localized endoscopic (n=81) resections at the National Cancer Center in Korea between January 2001 and December 2014. Researchers excluded the remaining 256 patients due to treatment with preoperative chemoradiotherapy.

The researchers also compared the rates of distant recurrence-free survival (DRFS) and overall survival (OS) between the surgical and endoscopic groups.


Continue Reading

Patients were subdivided into favorable and unfavorable populations depending on independent risk factors suggestive of lymph node metastasis. The favorable subpopulation exhibited a combination of the following 5 risk factors:

  • positive resection margin only or unconditional for margin status;
  • deep submucosal invasion only;
  • budding only;
  • no background adenoma only; and
  • budding plus no background adenoma.

The surgical group demonstrated higher rates of DRFS and OS compared with the endoscopic group (hazard ratio [HR], 0.20; 95% CI, 0.06-0.61; P =.0045 vs HR, 0.41; 95% CI, 0.25-0.70; P =.0010, respectively).

However, when comparing surgical and endoscopic resection groups in the favorable subpopulation only, no significant difference existed in DRFS and OS between the 2 groups (HR, 0.26; 95% CI, 0.02-4.19; P =.3431 vs HR, 0.58; 95% CI, 0.27-1.23; P =.1534, respectively).

“Although it is still standard that surgery should be recommended for the patients with high-risk T1 CRC, intensive surveillance without additional surgery may be another option in selected patients following endoscopic resection of high-risk T1 CRC,” the study authors said.

Study limitations include the retrospective, single-center design; the presence of a selection bias as evidenced by poorer histology in the surgical resection group compared with the localized resection group; and problems with conducting a fully randomized study due to ethical considerations.

Reference

Ha RK, Park B, Han KS, et al. Subpopulation analysis of survival in high-risk T1 colorectal cancer: surgery versus endoscopic resection only. Gastrointest Endosc. Published online July 18, 2022. doi:10.1016/j.gie.2022.07.016

This article originally appeared on Gastroenterology Advisor



Source link

Previous Post

Mystery Illness That Killed Dozens Of Dogs In Michigan Identified

Next Post

The Key to Reversing All Autoimmune Diseases

Next Post

The Key to Reversing All Autoimmune Diseases

Recommended

Implementation science helps usher innovation into health care

August 11, 2022

FDA Approves Durvalumab Plus Chemo for Biliary Tract Cancer

September 5, 2022

Don't miss it

Pharmaceutical

ALS Association battles its chapters over money, priorities

February 3, 2023
Medicines & Healthy Lifestyle

Surgery and Prescriptions Now Advised for Obese Children?

February 3, 2023
Medicines & Healthy Lifestyle

Jesduvroq Approved for Anemia of CKD in Patients on Dialysis

February 3, 2023
Medicines & Healthy Lifestyle

Prescribing Medication Dosage According To DNA Profile Lowers Side Effects By 30%: Study

February 3, 2023
News

Longer Diabetes Duration Links With Increased Heart Failure

February 3, 2023
Pharmaceutical

Health Bulletin 3/ February/ 2023

February 3, 2023

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.